Jing Ding1,
Wei Xu1,
Xiao-yan Cheng2,
Xi-hai Chen3,
Wen-jun Zhou4,
Rong Ma1,
Fan-ling Meng1 
For correspondence:- Fan-ling Meng Email: dr_mfl1979@126.com Tel:+8613100938267
Accepted: 3 May 2023 Published: 30 May 2023
Citation: Ding J, Xu W, Cheng X, Chen X, Zhou W, Ma R, et al. Effectiveness of nab-paclitaxel versus traditional paclitaxels in the treatment of ovarian cancer. Trop J Pharm Res 2023; 22(5):1043-1050 doi: 10.4314/tjpr.v22i5.16
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To evaluate the effect of four taxane drugs, namely, paclitaxel, docetaxel, paclitaxel liposomes (Lipusu), and nab-paclitaxel (Keaili) on ovarian cancer cells both in vivo and in vitro.
Methods: BALB/c-nu/nu female mice were used to develop mouse xenograft models. The mice were randomized to 5 groups (4 in each group), namely, control (PBS) group, paclitaxel group, docetaxel group, liposomal paclitaxel group and nab-paclitaxel group. The effect of four taxane drugs were determined via cell proliferation and toxicity tests. Mouse xenograft models were employed to assess the efficacy of four taxane drugs in inhibiting tumor growth.
Results: Nab-paclitaxel has a significant ovarian growth-reducing effect in vitro. In vivo, no significant differences were observed in tumor volume among the four groups (p < 0.05). Nab-paclitaxel produced the lowest animal toxicity when compared with other three drugs as the mice in nab-paclitaxel treatment group showed no significant alterations in body weight (p < 0.05). Hematoxylin and eosin (H & E) staining revealed the lowest degree of liver tissue damage in mice treated with nab-paclitaxel compared to mice administered the other three paclitaxels.
Conclusion: Nab-paclitaxel is more effective in mice with ovarian cancer than traditional paclitaxels. Thus, it promises to offer a viable alternative as first-line chemotherapy for epithelial ovarian cancer in humans, as it has low systemic toxicity and fewer hypersensitivity reactions. However, further investigations, including clinical trials in humans, are required
Fulltext in PDF
